Plasminogen activator inhibitor-1 and type 2 diabetes: A systematic review and meta-analysis of observational studies

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yarmolinsky, James ^a   Bordin Barbieri, Natália ^a   Weinmann, Tobias ^b   Ziegelmann, Patricia K ^a   Duncan, Bruce B ^a   Inês Schmidt, Maria ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; HUMAN; META ANALYSIS; METABOLISM; ODDS RATIO; PROSPECTIVE STUDY;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES;

EID: 84955518089     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17714     Document Type: Article

References (112)

1. Grant, P.J. Diabetes mellitus as a prothrombotic condition. J Intern Med. 262, 157-72 (2007).
2. Schäfer, K., Fujisawa, K., Konstantinides, S., Loskutoff, D.J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 15, 1840-2 (2001).
3. Ma, L.J. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53, 336-46 (2004).
4. Festa A. et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 19, 562-8 (1999).
5. Alessi M.C. et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 46, 860-7 (1997).
6. Meigs, J.B. et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 283, 221-8 (2000).
7. Al-Hamodi, Z., Ismail, I.S., Saif-Ali, R., Ahmed, K.A., Muniandy, S. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol. 10, 23 (2011).
8. Nagi, D.K., Ali, V.M., Jain, S.K., Walji, S., Yudkin, J.S. Plasminogen Activator inhibitor (PAI-1) activity is elevated in asian and caucasian subjects with non-insulin-dependent (Type 2) Diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Diabet Med. 13, 59-64 (1996).
9. Festa, A., D'Agostino, R., Tracy, R.P., Haffner, S.M. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes. 51, 1131-7 (2002).
10. Eliasson, M.C., Jansson, J.H., Lindahl, B., Stegmayr, B. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study. Cardiovasc Diabetol. 2, 19 (2003).
11. Kanaya, A.M. et al. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care. 27, 1375-80 (2004).
12. Kanaya, A.M. et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med. 166, 350-6 (2006).
13. Verkleij, C.J. et al. The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease. Clin Appl Thromb Hemost. 17, E57-63 (2011).
14. Soares, A.L. et al. PAI-1 and D-dimer in type 2 diabetic women with asymptomatic macrovascular disease assessed by carotid Doppler. Clin Appl Thromb Hemost. 16, 204-8 (2010).
15. Kitagawa, N. et al. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract. 73, 150-7 (2006).
16. Hughes, K., Choo, M., Kuperan, P., Ong, C.N., Aw, T.C. Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population-based survey among Asians in Singapore. Atherosclerosis. 136, 25-31 (1998).
17. DeClerck, PJ., Alessi, MC., Verstreken M., Kruithof, EK., Juhan-Vague, I., Collen, D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 71, 220-5 (1988).
18. Stroup, D.F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-12 (2000).
19. Wells, G. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2011) Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. (Accessed 22 October 2014).
20. Danesh, J., Collins, R., Appleby, P., Peto, R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477-82 (1998).
21. Alessi, M.C. et al. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort. Thromb Haemost. 106, 416-22 (2011).
22. Hernestal-Boman, J. et al. Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a populationbased study. Cardiovasc Diabetol. 11, 152 (2012).
23. Meigs, J.B. et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes The Framingham Offspring Study. Diabetes. 55, 530-7 (2006).
24. Davidson, M. et al. Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 23, 1158-9 (2006).
25. Begg, C.B., Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-101 (1994).
26. Egger, M., Davey Smith, G., Schneider, M., Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-34 (1997).
27. Stranges, S. et al. Additional contribution of emerging risk factors to the prediction of the risk of type 2 diabetes: evidence from the Western New York Study. Obesity. 16, 1370-6 (2008).
28. Raji, M.A., Al Snih, S., Ray, L.A., Patel, K.V., Markides, K.S. Cognitive status and incident disability in older Mexican Americans: findings from the Hispanic established population for the epidemiological study of the elderly. Ethn Dis. 14, 26-31 (2004).
29. Lutsey, P.L. et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost. 4, 2629-35 (2006).
30. Festa, A. et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: The Insulin Resistance Atherosclerosis Study. Circulation. 107, 2422-7 (2003).
31. Oldroyd, J., Banerjee, M., Heald, A., Cruickshank, K. Diabetes and ethnic minorities. Postgrad Med J. 81, 486-90 (2005).
32. Palaniappan, L.P., Carnethon, M.R., Fortmann, S.P. Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin. Diabetes Care 25, 1351-7 (2002).
33. Schmidt, M.I. et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353, 1649-52 (1999).
34. Duncan, B.B. et al. Factor VIII and other hemostasis variables are related to incident diabetes in adults. Diabetes Care 22, 767-72 (1999).
35. Wannamethee, S.G. et al. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 31, 995-1000 (2008).
36. Thorand, B. et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol. 26, 398-405 (2006).
37. Song, Y. et al. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes 56, 1898-904 (2007).
38. Lowe, G.D.O., Rumley, A., Whincup, P.H., Danesh, J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med. 2, 429-39 (2002).
39. Festa, A., Williams, K., Tracy, R.P., Wagenknecht, L.E., Haffner, S.M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation. 113, 1753-9 (2006).
40. Huang, J. et al. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood. 120, 4873-81 (2012).
41. Lee, K.W., Lip, G.Y.H. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity. Arch Intern Med. 163, 2368-92 (2003).
42. Nagi, D.K., Yudkin, J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16, 621-29 (1993).
43. Fonseca, V.A. et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12, 181-86 (1998).
44. Ingelsson, E. et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. Circulation. 116, 984-92 (2007).
45. Mertens, I., Van Gaal, L.F. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 3, 85-101 (2002).
46. Shimomura, I. et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 2, 800-3 (1996).
47. Alessi, M.C. et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 46, 860-7 (1997).
48. Halleux, C.M., Declerck, P.J., Tran, S.L., Detry, R., Brichard, S.M. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab. 84, 4097-105 (1999).
49. Landin, K. et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 39, 1044-8 (1990).
50. Janand-Delenne, B. et al. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord. 22, 312-7 (1998).
51. Giltay, E.J. et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol. 18, 1716-22 (1998).
52. Marckmann, P., Toubro, S., Astrup, A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr. 52, 329-333 (1998).
53. Aziz, CB. et al. Reduced fibrinogen, fibrinolytic biomarkers, and physical parameters after a weight-loss program in obese subjects. N Am J Med Sci. 6, 377-82 (2014).
54. Folsom, A.R. et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol. 13, 162-9 (1993).
55. Mavri, A. et al. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol. 19, 1582-7 (1999).
56. Dandona, P., Aljada, A., Bandyopadhyay, A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4-7 (2004).
57. Devaraj, S., Xu, D.Y., Jialal, I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 107, 398-404 (2003).
58. Alessi, M.C. et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 49, 1374-80 (2000).
59. Cigolini, M. et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis 143, 81-90 (1999).
60. Birgel, M., Gottschling-Zeller, H., Röhrig, K., Hauner, H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol. 20, 1682-7 (2000).
61. Singh, P. et al. Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells. Biochem Biophys Res Commun. 392, 47-52 (2010).
62. Komiya, M. et al. Bi-directional regulation between adiponectin and plasminogen activator-inhibitor-1 in 3T3-L1 cells. In Vivo. 28, 13-9 (2014).
63. Chen, G.C., Qin, L.Q., Ye, J.K. Leptin levels and risk of type 2 diabetes: gender-specific meta-analysis. Obes Rev. 15, 134-42 (2014).
64. Li, S., Shin, H.J., Ding, E.L., van Dam, R.M. Adiponectin levels and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA. 302, 179-88 (2009).
65. Samad, F., Pandey, M., Bell, P.A., Loskutoff, D.J. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med. 6, 680-92 (2000).
66. Bastard, J.P., Pieroni, L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother. 53, 455-61 (1999).
67. Sjoholm, A., Nystrom, T. Endothelial inflammation in insulin resistance. Lancet. 365, 610-2 (2005).
68. Pandolfi, A. et al. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia. 39, 1425-31 (1996).
69. Suzuki, M., Akimoto, K., Hattori, Y. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sci. 72, 59-66 (2002).
70. Gabriely, I. et al. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 160, 115-22 (2002).
71. Maiello, M. et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41, 1009-15 (1992).
72. Lee, C.C. et al. The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia 56, 112-20 (2013).
73. Azad, N. et al. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 37, 501-6 (2014).
74. Nicholas SB. et al. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 67, 1297-307 (2005).
75. Zhao, L., Huang, P. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk. Int J Clin Exp Med. 6, 632-40 (2013).
76. Auwerx, J., Bouillon, R., Collen, D., Geboers, J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8, 68-72 (1988).
77. Juhan-Vague, I. et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost. 61, 370-3 (1989).
78. Rydzewski, A., Kawamura, H., Watanabe, I., Takada, Y., Takada, A. Plasminogen activators and plasminogen activator inhibitor (PAI-1) in type II diabetes mellitus. Fibrinolysis 4, 183-8 (1990).
79. Cho, Y.W. et al. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis. Korean J Intern Med. 7, 81-6 (1992).
80. Potter van Loon, B.J., Kluft, C., Radder, J.K., Blankenstein, M.A., Meinders, A.E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 8, 945-9 (1993).
81. Takada, Y., Urano, T., Watanabe, I., Taminato, A., Yoshimi, T., Takada, A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res. 781, 405-15 (1993).
82. Avellone, G., Di Garbo, V., Cordova, R. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res. 25, 85-92 (1994).
83. Park, Y.S. et al. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea. Diabetes Res Clin Pract. 24, 25-31 (1994).
84. Kario, K. et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol. 15, 1114-20 (1995).
85. Ito, Y., Okeda, T., Sato, Y., Ito, M., Sakata, T. Plasminogen activator inhibitor-1 in nonobese subjects with non-insulindependent diabetes mellitus. Proc Soc Exp Biol Med. 211, 287-91 (1996).
86. Akanji, A.O., Abdullah, A., Tahzeeb, S. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait. Eur J Clin Invest. 27, 380-6 (1997).
87. Gray, R.P., Panahloo, A., Mohamed-Ali, V., Patterson, D.L.H., Yudkin, J.S. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis 130,171-8 (1997).
88. Krekora, K. et al. Decrease in urokinase-type plasminogen activator (u-PA) levels in patients with non-insulin dependent diabetes mellitus. Fibrinolysis & Proteolysis 4, 215-9 (1997).
89. Bannan, S., Mansfield, M.W., Grant, P.J. Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients. Diabetologia 41, 460-6 (1998).
90. Temelkova-Kurktschiev, T., Siegert, G., Koehler, C., Henkel, E., Hanefeld, E. Impaired fibrinolysis and early atherosclerosis in impaired glucose tolerance and newly detected type 2 diabetes. Fibrinolysis & Proteolysis 13, 11-5 (1999).
91. Testa, R. et al. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulindependent diabetes mellitus without complications. Int J Clin Lab Res. 28, 187-191 (1998).
92. Testa, R. et al. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients. Diab Nutr Metab. 12, 400-6 (1999).
93. Hernandez, C., Chacon, P., Garcia-Pascual, L., Mesa, J., Simo, R. Relationship between lipoprotein(a) phenotypes and plasminogen activator inhibitor type 1 in diabetic patients. Thromb Res. 15, 119-27 (2000).
94. Testa, R. et al. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications. Diab. Nutr. Metab. 13, 269-275 (2000).
95. Zareba, W. et al. Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. Thromb Haemost. 86, 791-9 (2001).
96. Aso, Y. et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism. 51, 471-6 (2002).
97. Brandenburg, S.L. et al. Impaired fibrinolysis in premenopausal women and age-matched men with Type 2 diabetes mellitus: a pilot study. J Investig Med. 50, 110-5 (2002).
98. Leurs, P.B. et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 25, 1340-5 (2002).
99. Fattah, M.A., Shaheen, M.H., Mahfouz, M.H. Disturbances of haemostasis in diabetes mellitus. Dis Markers. 19, 251-8 (2004).
100. Yu, Y., Suo, L., Yu, H., Wang, C., Tang, H. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract. 65, 95-104 (2004).
101. Erem, C. et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract. 14, 22-30 (2005).
102. Soares, A.L. et al. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers. Blood Coagul Fibrinolysis. 18, 395-9 (2007).
103. Le, D.S. et al. The association of plasma fibrinogen concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes. Diabetes Res Clin Pract. 82, 317-23 (2008).
104. Romuk, E. et al. Evaluation of VCAM-1 and PAI-1 concentration in diabetes mellitus patients. Diabet Do?w i Klin. 8, 85-8 (2008).
105. Sahli, D., Eriksson, J.W., Boman, K., Svensson, M.K. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thromb Res. 123, 701-6 (2009).
106. Jax, T.W., Peters, A.J., Plehn, G., Schoebel, F.C. Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2. Cardiovasc Diabetol. 8, 24 (2009).
107. Blaszkowski, A., Galar, M., Sokolowski, J., Kloczko, J. Plasminogen activator inhibitor-1 and thrombin activable fibrinolysis inhibitor in patients with type 2 diabetes. Diabetologia 53 [Supp 1]: S525 (2010).
108. Kubisz, P. et al. Circulating vascular endothelial growth factor in the normo-and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetologica. 47, 119-124 (2010).
109. Kovalyova, O., Ambrosova, T., Shapovalova, S. Diabetes is associated with hypoadiponectinema and elevated levels of TNFalpha, PAI-1 in obese hypertensive patients. Journal of Diabetes 3 [Supplement S1]:45 (2011) (Abstract).
110. Mertens, I. et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res. 33, 602-7 (2001).
111. Zhong, Z.L., Chen, S. Plasma plasminogen activator inhibitor-1 is associated with end-stage proliferative diabetic retinopathy in the Northern Chinese Han population. Exp Diabetes Res. 2012, 350852 (2012).
112. Brazionis, L., Rowley, K., Jenkins, A., Itsiopoulos, C., O'Dea, K. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler Thromb Vasc Biol. 28, 786-91 (2008).